
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Waikoloa, Hawaii - A investigational foam preparation of clindamycin phosphate 1 percent (Actiza) provides a safe, effective, well-tolerated, and innovative new treatment for acne vulgaris, said Lawrence F. Eichenfield, MD, at the annual Hawaii Dermatology Seminar in January.






